E-cadherin: Its dysregulation in carcinogenesis and clinical implications

Critical Reviews in Oncology/Hematology

Volumn 121, Issue , 2018, Pages 11-22

  Wong, Sonia How Ming ^a   Fang, Chee Mun ^a   Chuah, Lay Hong ^b   Leong, Chee Onn ^c   Ngai, Siew Ching ^a  

^a UNIVERSITY OF NOTTINGHAM MALAYSIA CAMPUS   (Malaysia)

^b MONASH UNIVERSITY MALAYSIA   (Malaysia)

^c INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Apoptosis; Carcinogenesis; Dysregulation; E cadherin; Invasiveness

Indexed keywords

MICRORNA; UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; APOPTOSIS; CANCER CELL; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL ADHESION; CELL CYCLE; CELL GROWTH; DISEASE ASSOCIATION; EMBRYO DEVELOPMENT; EPIGENETICS; EPITHELIUM CELL; GENE EXPRESSION; HISTONE MODIFICATION; HUMAN; METHYLATION; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; RNA TRANSCRIPTION; TRANSCRIPTION REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; WNT SIGNALING;

CADHERINS; CARCINOGENESIS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASMS; WNT SIGNALING PATHWAY;

EID: 85035105719     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2017.11.010     Document Type: Review

References (188)

1. Acs, G., Lawton, T.J., Rebbeck, T.R., Livolsi, V.A., Zhang, P.J., Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am. J. Clin. Pathol. 115 (2001), 85–98.
2. Akhtar, K., Ara, A., Siddiqui, S.A., Sherwani, R., Diagnostic and prognostic significance of E-cadherin and vimentin in oral cancer metastasis. Ann. Pathol. Lab. Med. 3:1 (2016), A-08–A-13.
3. Alotaibi, H., Basilicata, M.F., Shehwana, H., Kosowan, T., Schreck, I., Braeutigam, C., et al. Enhancer cooperativity as a novel mechanism underlying the transcriptional regulation of E-cadherin during mesenchymal to epithelial transition. Biochim. Biophys. Acta 1849 (2015), 731–742.
4. Asgeirsson, K.S., Jónasson, J.G., Tryggvadóttir, L., Olafsdóttir, K., Sigurgeirsdóttir, J.R., Ingvarsson, S., et al. Altered expression of E-cadherin in breast cancer. patterns, mechanisms and clinical significance. Eur. J. Cancer 36 (2000), 1098–1106.
5. Ashkenazi, A., Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. J. Clin. Invest. 125 (2015), 487–489.
6. Ben-Porath, I., Thomson, M.W., Carey, V.J., Ge, R., Bell, G.W., Regev, A., et al. An embryonic stem cell−like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40 (2008), 499–507.
7. Bessonnard, S., Mesnard, D., Constam, D.B., PC7 and the related proteases Furin and Pace4 regulate E-cadherin function during blastocyst formation. J. Cell Biol. 210 (2015), 1185–1197.
8. Birchmeier, W., Behrens, J., Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim. Biophys. Acta 1198 (1994), 11–26.
9. Brabletz, T., To differentiate or not — routes towards metastasis. Nat. Rev. Cancer 12 (2012), 425–436.
10. Brzozowska, A., Sodolski, T., Duma, D., Mazurkiewicz, T., Mazurkiewicz, M., Evaluation of prognostic parameters of E-cadherin status in breast cancer treatment. Ann. Agr. Environ. Med. 19:3 (2012), 541–546.
11. Byler, S., Goldgar, S., Heerboth, S., Leary, M., Housman, G., Moulton, K., et al. Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res. 34 (2014), 1071–1078.
12. Cao, Q., Yu, J., Dhanasekaran, S.M., Kim, J.H., Mani, R.S., Tomlins, S.A., et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27 (2008), 7274–7284.
13. Capaldo, C.T., Farkas, A.E., Nusrat, A., Epithelial adhesive junctions. F1000Prime Rep., 6, 2014, 1.
14. Celià-Terrassa, T., Meca-Cortés, Ó, Mateo, F., Martínez de Paz, A., Rubio, N., Arnal-Estapé, A., et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J. Clin. Invest. 122 (2012), 1849–1868.
15. Chao, Y.L., Shepard, C.R., Wells, A., Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol. Cancer, 9, 2010, 179.
16. Chao, Y., Wu, Q., Acquafondata, M., Dhir, R., Wells, A., Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron. 5 (2012), 19–28.
17. Chao, Y., Wu, Q., Shepard, C., Wells, A., Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clin. Exp. Metastasis 29 (2012), 39–50.
18. Chen, A., Beetham, H., Black, M.A., Priya, R., Telford, B.J., Guest, J., et al. E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. BMC Cancer, 14, 2014, 552.
19. Chen, L., Jian, W., Lu, L., Zheng, L., Yu, Z., Zhou, D., Elevated expression of E-cadherin in primary breast cancer and its corresponding metastatic lymph node. Int. J. Clin. Exp. Med. 8 (2015), 11752–11758.
20. Chen, D., Dai, F., Chen, Z., Wang, S., Cheng, X., Sheng, Q., et al. Dimethoxy curcumin induces apoptosis by suppressing survivin and inhibits invasion by enhancing E-cadherin in colon cancer cells. Med. Sci. Monit. 22 (2016), 3215–3222.
21. Christman, J.K., 5-Azacytidine and 5-aza-2-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21:35 (2002), 5483–5495.
22. Christou, N., Perraud, A., Blondy, S., Jauberteau, M.-O., Battu, S., Mathonnet, M., E-cadherin: a potential biomarker of colorectal cancer prognosis (Review). Oncol. Lett. 13 (2017), 4571–4576.
23. Corso, G., Carvalho, J., Marrelli, D., Vindigni, C., Carvalho, B., Seruca, R., et al. Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J. Clin. Oncol. 31 (2013), 868–875.
24. Daniels, D.L., Weis, W.I., β-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat. Struct. Mol. Biol. 12 (2005), 364–371.
25. Daraĩ, E., Scoazec, J.-Y., Walker-Combrouze, F., Mlika-Cabanne, N., Feldmann, G., Madelenat, P., et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum. Pathol. 28 (1997), 922–928.
26. Davis, M.A., Ireton, R.C., Reynolds, A.B., A core function for p120-catenin in cadherin turnover. J. Cell Biol. 163 (2003), 525–534.
27. De Craene, B., Gilbert, B., Stove, C., Bruyneel, E., Roy van, F., Berx, G., The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program. Cancer Res. 65 (2005), 6237–6244.
28. De Leeuw, W.J., Berx, G., Vos, C.B., Peterse, J.L., Van de Vijver, M.J., Litvinov, S., et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J. Pathol. 183 (1997), 404–411.
29. Dong, C., Wu, Y., Wang, Y., Wang, C., Kang, T., Rychahou, P.G., et al. Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer. Oncogene 32 (2013), 1351–1362.
30. Edelstein, M.L., Abedi, M.R., Wixon, J., Gene therapy clinical trials worldwide to 2007—an update. J. Gene Med. 9 (2007), 833–842.
31. Ellis, I.O., Galea, M., Broughton, N., Locker, A., Blamey, R.W., Elston, C.W., Pathological prognostic factors in breast cancer II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 20 (1992), 479–489.
32. Fan, L.C., Teng, H.W., Shiau, C.W., Tai, W.T., Hung, M.H., Yang, S.H., et al. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer. Oncotarget, 7, 2016, 64136.
33. Ferreira, P., Oliveira, M.J., Beraldi, E., Mateus, A.R., Nakajima, T., Gleave, M., et al. Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro. Exp. Cell Res. 310 (2005), 99–104.
34. Fierro-González, J.C., White, M.D., Silva, J.C., Plachta, N., Cadherin-dependent filopodia control preimplantation embryo compaction. Nat. Cell Biol. 15 (2013), 1424–1433.
35. Fisher, M.L., Adhikary, G., Grun, D., Kaetzel, D.M., Eckert, R.L., The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane. Mol. Carcinog. 55 (2016), 2024–2036.
36. Fleming, T.P., Javed, Q., Hay, M., Epithelial differentiation and intercellular junction formation in the mouse early embryo. Dev. Suppl. 116 (1992), 105–112.
37. Frixen, U.H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., et al. E-cadherin-mediated cell–cell adhesion prevents invasiveness of human carcinoma cells. J. Cell Biol. 113 (1991), 173–185.
38. Fujita, Y., Krause, G., Scheffner, M., Zechner, D., Leddy, H.E., Behrens, J., et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat. Cell Biol. 4 (2002), 222–231.
39. Fukagawa, A., Ishii, H., Miyazawa, K., Saitoh, M., δ EF1 associates with DNMT1 and maintains DNA methylation of the E-cadherin promoter in breast cancer cells. Cancer Med. 4 (2015), 125–135.
40. Fulda, S., Debatin, K.M., Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25 (2006), 4798–4811.
41. Gamallo, C., Palacios, J., Suarez, A., Pizarro, A., Navarro, P., Quintanilla, M., et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am. J. Pathol. 142 (1993), 987–993.
42. Gao, M., Zhang, X., Li, D., He, P., Tian, W., Zeng, B., Expression analysis and clinical significance of eIF4E, VEGF-C, E-cadherin and MMP-2 in colorectal adenocarcinoma. Oncotarget 7 (2016), 85502–85514.
43. Gillett, C.E., Miles, D.W., Ryder, K., Skilton, D., Liebman, R.D., Springall, R.J., et al. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J. Pathol. 193 (2001), 433–441.
44. Gonzalvez, F., Ashkenazi, A., New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 29 (2010), 4752–4765.
45. Gottardi, C.J., Wong, E., Gumbiner, B.M., E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J. Cell Biol. 153 (2001), 1049–1060.
46. Grabitz, A.L., Duncan, M.K., Focus on molecules: smad interacting protein 1 (Sip1, ZEB2, ZFHX1B). Exp. Eye Res. 101 (2012), 105–106.
47. Grabowska, M.M., Day, M.L., Soluble E-cadherin: more than a symptom of disease. Front. Biosci. 17:5 (2012), 1948–1964.
48. Gregory, D.J., Mikhaylova, L., Fedulov, A.V., Selective DNA demethylation by fusion of TDG with a sequence-specific DNA-binding domain. Epigenet 7:4 (2012), 344–349.
49. Gunasinghe, N.P., Wells, A., Thompson, E.W., Hugo, H.J., Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev. 31 (2012), 469–478.
50. Guriec, N., Marcellin, L., Gairard, B., Caldéroli, H., Wilk, A., Renaud, R., et al. E-cadherin mRNA expression in breast carcinomas correlates with overall and disease-free survival. Invas. Metastasis 16 (1996), 19–26.
51. Gurnani, M., Lipari, P., Dell, J., Shi, B., Nielsen, L.L., Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck ovarian, prostate, and breast cancer. Cancer Chemother. Pharmacol. 44 (1999), 143–151.
52. Hajra, K.M., Ji, X., Fearon, E.R., Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 18 (1999), 7274–7279.
53. Halbleib, J.M., Nelson, W.J., Cadherins in development: cell adhesion sorting, and tissue morphogenesis. Genes Dev. 20 (2006), 3199–3214.
54. Harrison, O.J., Jin, X., Hong, S., Bahna, F., Ahlsen, G., Brasch, J., et al. The extracellular architecture of adherens junctions revealed by crystal structures of type I cadherins. Structure 19 (2011), 244–256.
55. He, T.C., Sparks, A.B., Rago, C., Hermeking, H., Zawel, L., Costa, L.T., et al. Identification of c-MYC as a target of the APC pathway. Science 281 (1998), 1509–1512.
56. Hollestelle, A., Peeters, J.K., Smid, M., Timmermans, M., Verhoog, L.C., Westenend, P.J., et al. Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer. Breast Cancer Res. Treat. 138 (2013), 47–57.
57. Horne, H.N., Sherman, M.E., Garcia-Closas, M., Pharoah, P.D., Blows, F.M., Yang, X.R., et al. Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression. Breast Cancer Res. Treat. 143 (2014), 181–187.
58. Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., et al. Drug resistance in cancer: an overview. Cancers (Basel) 6 (2014), 1769–1792.
59. Hsu, M.Y., Meier, F.E., Nesbit, M., Hsu, J.Y., Belle Van, P., Elder, D.E., et al. E-Cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am. J. Pathol. 156 (2000), 1515–1525.
60. Hu, X.C., Loo, W.T., Chow, L.W., E-cadherin promoter methylation can regulate its expression in invasive ductal breast cancer tissue in Chinese woman. Life Sci. 71 (2002), 1397–1404.
61. Hudson, L.G., Zeineldin, R., Stack, M.S., Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin. Exp. Metastasis 25 (2008), 643–655.
62. Hulsken, J., Birchmeier, W., Behrens, J., E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J. Cell Biol. 127 (1994), 2061–2069.
63. Iglesias, J.M., Beloqui, I., Garcia-Garcia, F., Leis, O., Vazquez-Martin, A., Eguiara, A., et al. Mammosphere formation in breast carcinoma cell lines depends upon expression of E-cadherin. PLoS One, 8, 2013, e77281.
64. Ishiyama, N., Lee, S.H., Liu, S., Li, G.Y., Smith, M.J., Reichardt, L.F., et al. Dynamic and static interactions between p120 catenin and E-cadherin regulate the stability of cell–cell adhesion. Cell 141 (2010), 117–128.
65. Jeanes, A., Gottardi, C.J., Yap, A.S., Cadherins and cancer: how does cadherin dysfunction promote tumor progression?. Oncogene 27 (2008), 6920–6929.
66. Jiang, W.G., Mansel, R.E., E-cadherin complex and its abnormalities in human breast cancer. Surg. Oncol. 9 (2000), 151–171.
67. Jiang, W.G., E-cadherin and its associated protein catenins: cancer invasion and metastasis. Br. J. Surg. 83 (1996), 437–446.
68. Jie, D., Zhongmin, Z., Guoqing, L., Sheng, L., Yi, Z., Jing, W., et al. Positive expression of LSD1 and negative expression of E-cadherin correlate with metastasis and poor prognosis of colon cancer. Digest. Dis. Sci. 58 (2013), 1581–1589.
69. Jou, T.S., Stewart, D.B., Stappert, J., Nelson, W.J., Marrs, J.A., Genetic and biochemical dissection of protein linkages in the cadherin-catenin complex. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 5067–5071.
70. Katayama, M., Hirai, S., Kamihagi, K., Nakagawa, K., Yasumoto, M., Kato, I., Soluble E-cadherin fragments increased in circulation of cancer patients. Br. J. Cancer 69 (1994), 580–589.
71. Kim, S.A., Inamura, K., Yamauchi, M., Nishihara, R., Mima, K., Sukawa, Y., et al. Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. Br. J. Cancer 114 (2016), 199–206.
72. Koopmansch, B., Berx, G., Foidart, J.M., Gilles, C., Winkler, R., Interplay between KLF4 and ZEB2/SIP1 in the regulation of E-cadherin expression. Biochem. Biophys. Res. Commun. 431 (2013), 652–657.
73. Kowalski, P.J., Rubin, M.A., Kleer, C.G., E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 5 (2003), R217–R222.
74. Lagendijk, A.K., Hogan, B.M., VE-cadherin in vascular development: a coordinator of cell signaling and tissue morphogenesis. Curr. Top. Dev. Biol. 112 (2015), 325–352.
75. Larue, L., Ohsugi, M., Hirchenhain, J., Kemler, R., E-cadherin null mutant embryos fail to form a trophectoderm epithelium. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 8263–8267.
76. Lau, M.T., So, W.K., Leung, P.C., Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS One, 8(3), 2013, e59083.
77. Leckband, D., Prakasam, A., Mechanism and dynamics of cadherin adhesion. Annu. Rev. Biomed. Eng. 8 (2006), 259–287.
78. Li, S.D., Huang, L., Gene therapy progress and prospects: non-viral gene therapy by systemic delivery. Gene Ther. 13 (2006), 1313–1319.
79. Li, L.N., Zhang, H.D., Yuan, S.J., Yang, D.X., Wang, L., Sun, Z.X., Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and E-cadherin. Eur. J. Pharmacol. 588 (2008), 1–8.
80. Li, G., Liu, Y., Yin, H., Zhang, X., Mo, X., Tang, J., et al. E-cadherin gene promoter hypermethylation may contribute to the risk of bladder cancer among Asian populations. Gene 534 (2013), 48–53.
81. Li, Y., Kong, D., Ahmad, A., Bao, B., Sarkar, F.H., MicroRNA targeted therapy for overcoming drug resistance: reversal of EMT and elimination of cancer stem cells in prostate and pancreatic cancer. MicroRNA Target. Cancer Ther., 2014, 199–217.
82. Lishman, S.C., Lakhani, S.R., Atypical lobular hyperplasia and lobular carcinoma in situ: surgical and molecular pathology. Histopathology 35 (1999), 195–200.
83. Liu, X., Chu, K.-M., E-cadherin and gastric cancer: cause, consequence, and applications. BioMed Res. Int., 637308, 2014.
84. Liu, S., Kumar, S.M., Lu, H., Liu, A., Yang, R., Pushparajan, A., et al. MicroRNA-9 up-regulates E-cadherin through inhibition of NF-(B1-Snail1 pathway in melanoma. J. Pathol. 226 (2012), 61–72.
85. Liu, T., Zhang, X., Shang, M., Zhang, Y., Xia, B., Niu, M., et al. Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer. J. Surg. Oncol. 107 (2013), 188–194.
86. Liu, X., Huang, H., Remmers, N., Hollingsworth, M.A., Loss of E-cadherin and epithelial to mesenchymal transition is not required for cell motility in tissues or for metastasis. Tissue Barriers, 2, 2014, e969112.
87. Louie, E., Chen, X.F., Coomes, A., Ji, K., Tsirka, S., Chen, E.I., Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis. Oncogene 32 (2013), 4064–4077.
88. Lowy, A.M., Knight, J., Groden, J., Restoration of E-cadherin/beta-catenin expression in pancreatic cancer cells inhibits growth by induction of apoptosis. Surgery 132 (2002), 141–148.
89. Lu, M., Marsters, S., Ye, X., Luis, E., Gonzalez, L., Ashkenazi, A., E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis. Mol. Cell. 54 (2014), 987–998.
90. Luo, M., Li, Z., Wang, W., Zeng, Y., Liu, Z., Qiu, J., Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett. 333 (2013), 213–221.
91. Ma, L., Young, J., Prabhala, H., Pan, E., Mestdagh, P., Muth, D., et al. miR-9 a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12 (2010), 247–256.
92. Ma, D.N., Chai, Z.T., Zhu, X.D., Zhang, N., Zhan, D.H., Ye, B.G., et al. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2. J. Hematol. Oncol., 9, 2016, 1.
93. MacDonald, B.T., Tamai, K., He, X., Wnt/beta-Catenin Signaling: components mechanisms, and diseases. Dev. Cell 17 (2009), 9–26.
94. Maroni, P., Matteucci, E., Drago, L., Banfi, G., Bendinelli, P., Desiderio, M.A., Hypoxia induced E-cadherin involving regulators of Hippo pathway due to HIF-1α stabilization/nuclear translocation in bone metastasis from breast carcinoma. Exp. Cell Res. 330 (2015), 287–299.
95. Masciari, S., Larsson, N., Senz, J., Boyd, N., Kaurah, P., Kandel, M.J., et al. Germline E-cadherin mutations in familial lobular breast cancer. J. Med. Genet. 44 (2007), 726–731.
96. Matsumura, T., Makino, R., Mitamura, K., Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin. Cancer Res. 7 (2001), 594–599.
97. Mayer, B., Johnson, J.P., Leitl, F., Jauch, K.W., Heiss, M.M., Schildberg, F.W., et al. E-Cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res. 53 (1993), 1690–1695.
98. Mesri, M., Wall, N.R., Li, J., Kim, R.W., Altieri, D.C., Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest. 108 (2001), 981–990.
99. Moll, R., Mitze, M., Frixen, U.H., Birchmeier, W., Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am. J. Pathol. 143 (1993), 1731–1742.
100. Momparler, R.L., Epigenetic therapy of cancer with 5-aza-2-deoxycytidine (decitabine). Semin. Oncol. 32:5 (2005), 443–451.
101. Moreno-Bueno, G., Cubillo, E., Sarrió, D., Peinado, H., Rodríguez-Pinilla, S.M., Villa, S., et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res. 66 (2006), 9543–9556.
102. Motti, M.L., Califano, D., Baldassarre, G., Celetti, A., Merolla, F., Forzati, F., et al. Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis 26 (2005), 1021–1034.
103. Murgo, A.J., Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs. Semin. Oncol. 32:5 (2005), 458–464.
104. Myong, N.-H., Loss of E-cadherin and Acquisition of vimentin in Epithelial-Mesenchymal transition are noble indicators of Uterine Cervix Cancer progression. Korean J. Pathol. 46 (2012), 341–348.
105. Nagar, B., Overduin, M., Ikura, M., Rini, J.M., Structural basis of calcium-induced E-cadherin rigidification and dimerization. Nature 380 (1996), 360–364.
106. Ngai, S.C., Epigenetics interplay between DNA methylation and histone modifications in breast cancer. Adv. Genet. Eng. Biotechnol., 1, 2012, 1.
107. Nickel, A., Stadler, S.C., Role of epigenetic mechanisms in epithelial-to-mesenchymal transition of breast cancer cells. Transl. Res. 165 (2015), 126–142.
108. Niemhom, S., Kitazawa, S., Kitazawa, R., Maeda, S., Leopairat, J., Hypermethylation of epithelial-cadherin gene promoter is associated with Epstein-Barr virus in nasopharyngeal carcinoma. Cancer Detect. Prev. 32 (2008), 127–134.
109. Nieset, J.E., Redfield, A.R., Jin, F., Knudsen, K.A., Johnson, K.R., Wheelock, M.J., Characterization of the interactions of α −catenin with α −actinin and β-catenin/plakoglobin. J. Cell Sci. 110 (1997), 1013–1022.
110. O'Day, E., Lal, A., MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res., 12, 2010, 201.
111. Ogou, S.I., Yoshida-Noro, C., Takeichi, M., Calcium-dependent cell–cell adhesion molecules common to hepatocytes and teratocarcinoma stem cells. J. Cell Biol. 97 (1983), 944–948.
112. Oka, H., Shiozaki, H., Kobayashi, K., Inoue, M., Tahara, H., Kobayashi, T., et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 53 (1993), 1696–1701.
113. Pai, K., Baliga, P., Shrestha, B.L., E-Cadherin expression: a diagnostic utility for differentiating breast carcinomas with ductal and lobular morphologies. J. Clin. Diag. Res. 7:5 (2013), 840–844.
114. Palacios, J., Sarrió, D., García-Macias, M.C., Bonita Bryant Sobel, M.E., Merino, M.J., Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast. Mod. Pathol. 16:7 (2003), 674–678.
115. Palen, K., Weber, J., Dwinell, M.B., Johnson, B.D., Ramchandran, R., Gershan, J.A., E-cadherin re-expression shows in vivo evidence for mesenchymal to epithelial transition in clonal metastatic breast tumor cells. Oncotarget 7 (2016), 43363–43364.
116. Park, J., Jang, K.L., Hepatitis C virus represses E-cadherin expression via DNA methylation to induce epithelial to mesenchymal transition in human hepatocytes. Biochem. Biophys. Res. Commun. 446 (2014), 561–567.
117. Pećina-Šlaus, N., Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int., 3, 2003, 17.
118. Peifer, M., Polakis, P., Wnt signaling in oncogenesis and embryogenesis?a look outside the nucleus. Science 287 (2000), 1606–1609.
119. Peinado, H., Olmeda, D., Cano, A., Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat. Rev. Cancer 7 (2007), 415–428.
120. Puliafito, A., Hufnagel, L., Neveu, P., Streichan, S., Sigal, A., Fygenson, D.K., et al. Collective and single cell behavior in epithelial contact inhibition. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 739–744.
121. Qian, X., Huang, C., Cho, C.H., Hui, W.M., Rashid, A., Chan, A.O., E-cadherin promoter hypermethylation induced by interleukin-1beta treatment or H. pylori infection in human gastric cancer cell lines. Cancer Lett. 263 (2008), 107–113.
122. Ran, J., Lin, D.L., Wu, R.F., Chen, Q.H., Huang, H.P., Qiu, N.X., et al. ZEB1 promotes epithelial-mesenchymal transition in cervical cancer metastasis. Fertil. Steril. 1614 (2015), e1–e2.
123. Raper, S.E., Chirmule, N., Lee, F.S., Wivel, N.A., Bagg, A., Gao, G.P., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80 (2003), 148–158.
124. Riethmacher, D., Brinkmann, V., Birchmeier, C., A targeted mutation in the mouse E-cadherin gene results in defective preimplantation development. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 855–859.
125. Romero-Pérez, L., López-García MÁ, Díaz-Martín, J., Biscuola, M., Castilla MÁ, Tafe, L.J., et al. ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Mod. Pathol. 26 (2013), 1514–1524.
126. Rosado, P., Lequerica-Fernández, P., Fernández, S., Allonca, E., Villallaín, L., JC.de, Vicente, E-cadherin and β-catenin expression in well-differentiated and moderately-differentiated oral squamous cell carcinoma: relations with clinical variables. Br. J. Oral Maxillofac. Surg. 51 (2013), 149–156.
127. Rothbart, S.B., Strahl, B.D., Interpreting the language of histone and DNA modifications. Biochim. Biophys. Acta 62:1839 (2014), 627–643.
128. Sarrió, D., Moreno-Bueno, G., Hardisson, D., Sánchez-Estévez, C., Guo, M., Herman, J.G., et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int. J. Cancer 106 (2003), 208–215.
129. Sasatomi, E., Tokunaga, O., Miyazaki, K., Spontaneous apoptosis in gallbladder carcinoma: relationships with clinicopathologic factors expression of E-cadherin, bcl-2 protooncogene, and p53 oncosuppressor gene. Cancer 78 (1996), 2101–2110.
130. Sawada, K., Mitra, A.K., Radjabi, A.R., Bhaskar, V., Kistner, E.O., Tretiakova, M., et al. Loss of E-Cadherin promotes ovarian cancer metastasis via alpha 5-Integrin, which is a therapeutic target. Cancer Res. 68 (2008), 2329–2339.
131. Schipper, J.H., Frixen, U.H., Behrens, J., Unger, A., Jahnke, K., Birchmeier, W., E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res. 51 (1991), 6328–6337.
132. Shah, P., Gau, Y., Sabnis, G., Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin. Breast Cancer Res. Treat. 143 (2014), 99–111.
133. Shen, C., Buck, A.K., Liu, X., Winkler, M., Reske, S.N., Gene silencing by adenovirus-delivered siRNA. FEBS Lett. 539 (2003), 111–114.
134. Shimoyama, Y., Hirohashi, S., Hirano, S., Noguchi, M., Shimosato, Y., Takeichi, M., et al. Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. Cancer Res. 49 (1989), 2128–2133.
135. Si, H.X., Tsao, S.W., Lam, K.Y., Srivastava, G., Liu, Y., Wong, Y.C., et al. E-cadherin expression is commonly downregulated by CpG island hypermethylation in esophageal carcinoma cells. Cancer Lett. 173 (2001), 71–78.
136. Siitonen, S.M., Kononen, J.T., Helin, H.J., Rantala, I.S., Holli, K.A., Isola, J.J., Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am. J. Clin. Pathol. 105 (1996), 394–402.
137. Singhai, R., Patil, V.W., Jaiswal, S.R., Patil, S.D., Tayade, M.B., Patil, A.V., E-Cadherin as a diagnostic biomarker in breast cancer. N. Am. J. Med. Sci. 3 (2011), 227–233.
138. Song, Y., Li, J., Zhu, Y., Dai, Y., Zeng, T., Liu, L., et al. MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma. Oncotarget 5 (2014), 11669–11680.
139. St Croix, B., Sheehan, C., Rak, J.W., Flørenes, V.A., Slingerland, J.M., Kerbel, R.S., E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J. Cell Biol. 142 (1998), 557–571.
140. Stockinger, A., Eger, A., Wolf, J., Beug, H., Foisner, R., E-cadherin regulates cell growth by modulating proliferation-dependent β −catenin transcriptional activity. J. Cell Biol. 154 (2001), 1185–1196.
141. Strathdee, G., Epigenetic versus genetic alterations in the inactivation of E-cadherin. Semin. Cancer Biol. 12 (2002), 373–379.
142. Suciu, C., Cimpean, A.M., Muresan, A.M., Izvernariu, D., Raica, M., E-cadherin expression in invasive breast cancer. Rom. J. Morphol. Embryo 49 (2008), 517–523.
143. Sugihara, T., Loss of adherens junction protein E-Cadherin is a biomarker of high- grade histology and poor prognosis in endometrial cancer. Ann. Clin. Lab Res., 4, 2016, 1.
144. Tahara, T., Shibata, T., Yamashita, H., Nakamura, M., Yoshioka, D., Okubo, M., et al. Chronic nonsteroidal anti-inflammatory drug (NSAID) use suppresses multiple CpG islands hyper methylation (CIHM) of tumor suppressor genes in the human gastric mucosa. Cancer Sci. 100 (2009), 1192–1197.
145. Tahara, T., Shibata, T., Nakamura, M., Yamashita, H., Yoshioka, D., Okubo, M., et al. Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa. Digest. Dis. Sci. 55 (2010), 54–59.
146. Takahashi, K., Suzuki, K., Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell–cell adhesion. Exp. Cell Res. 226 (1996), 214–222.
147. Takeichi, M., Functional correlation between cell adhesive properties and some cell surface proteins. J. Cell Biol. 75 (1977), 464–474.
148. Tan, E.J., Kahata, K., Idas, O., Thuault, S., Heldin, C.H., Moustakas, A., The high mobility group A2 protein epigenetically silences the Cdh1 gene during epithelial-to-mesenchymal transition. Nucleic Acids Res. 43 (2015), 162–178.
149. Tang, S.-N., Fu, J., Nall, D., Rodova, M., Shankar, S., Srivastava, R.K., Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int. J. Cancer 131 (2012), 30–40.
150. Teo, W.W., Merino, V.F., Cho, S., Korangath, P., Liang, X., Wu, R.C., et al. HOXA5 determines cell fate transition and impedes tumor initiation and progression in breast cancer through regulation of E-cadherin and CD24. Oncogene 35 (2016), 5539–5551.
151. Tessarz, P., Kouzarides, T., Histone core modifications regulating nucleosome structure and dynamics. Nat. Rev. Mol. Cell Biol. 15 (2014), 703–708.
152. Tetsu, O., McCormick, F., Beta-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398 (1999), 422–426.
153. Thiery, J.P., Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2 (2002), 442–454.
154. Tryndyak, V.P., Beland, F.A., Pogribny, I.P., E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int. J. Cancer, 126, 2010 2575–2383.
155. Tsai, J.H., Yang, J., Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 27 (2013), 2192–2206.
156. Umbas, R., Isaacs, W.B., Bringuier, P.P., Schaafsma, H.E., Karthaus, H.F., Oosterhof, G.O., et al. Decreased E-cad- herin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 54 (1994), 3929–3933.
157. Umbas, R., Isaacs, W.B., Bringuier, P.P., Xue, Y., Debruyne, F.M., Schalken, J.A., Relation between aberrant alpha-catenin expres- sion and loss of E-cadherin function in prostate cancer. Int. J. Cancer 74 (1997), 374–377.
158. Ungewiss, C., Rizvi, Z.H., Roybal, J.D., Peng, D.H., Gold, K.A., Shin, D.H., et al. The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL. Sci. Rep., 6, 2016, 18652.
159. Vandewalle, C., Comijn, J., Craene De, B., Vermassen, P., Bruyneel, E., Andersen, H., et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell–cell junctions. Nucleic Acids Res. 33 (2005), 6566–6578.
160. Veatch, A.L., Carson, L.F., Ramakrishnan, S., Differential expression of the cell–cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int. J. Cancer 58 (1994), 393–399.
161. Velikova, G., Banks, R.E., Gearing, A., Hemingway, I., Forbes, M.A., Preston, S.R., et al. Serum concentrations of soluble adhesion molecules in patients with colorectal cancer. Br. J. Cancer 77 (1998), 1857–1863.
162. Vesuna, F., Diest van, P., Chen, J.H., Raman, V., Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem. Biophys. Res. Commun. 367 (2008), 235–241.
163. Villarejo, A., Cortés-Cabrera, Á, Molina-Ortíz, P., Portillo, F., Cano, A., Differential role of Snail1 and Snail2 zinc fingers in E-cadherin repression and epithelial to mesenchymal transition. J. Biol. Chem. 289 (2014), 930–941.
164. Virani, S., Colacino, J.A., Kim, J.H., Rozek, L.S., Cancer epigenetics: a brief review. ILAR J. 53 (2012), 359–369.
165. Vleminckx, K., Vakaet, L., Mareel, M., Fiers, W., van Roy, F., Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66 (1991), 107–119.
166. Wahed, A., Connelly, J., Reese, T., E-cadherin expression in pleomorphic lobular carcinoma: an aid to differentiation from ductal carcinoma. Ann. Diagn. Pathol. 6 (2002), 349–351.
167. Wang, G., Hu, X., Lu, C., Su, C., Luo, S., Luo, Z.W., Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer. Lung Cancer 62 (2008), 162–172.
168. Wang, R., Ma, X., Li, Y., He, Y., Huang, D., Cai, S., et al. The characteristics and prognostic effect of E-cadherin expression in colorectal signet ring cell carcinoma. PLoS One, 11, 2016, e0160527.
169. West, J.J., Harris, T.J., Cadherin trafficking for tissue morphogenesis: control and consequences. Traffic 17 (2016), 1233–1243.
170. Wheelock, M.J., Johnson, K.R., Cadherins as modulators of cellular phenotype. Annu. Rev. Cell Dev. Biol. 19 (2003), 207–235.
171. Wong, T.S., Gao, W., Chan, J.Y.W., Interactions between E-Cadherin and microRNA deregulation in head and neck cancers: the potential interplay. BioMed. Res. Int., 2014, 2014, 126038.
172. Wu, Y., Liu, H.B., Ding, M., Liu, J.N., Zhan, P., Fu, X.S., et al. The impact of E-cadherin expression on non-small cell lung cancer survival: a meta- analysis. Mol. Biol. Rep. 39 (2012), 9621–9628.
173. Wu, J., Zhang, J.-R., Qin, J., Clinical significance of methylation of E-cadherin and p14ARF gene promoters in skin squamous cell carcinoma tissues. Int. J. Clin. Exp. Med. 7 (2014), 1808–1812.
174. Xing, X., Tang, Y.B., Yuan, G., Wang, Y., Wang, J., Yang, Y., et al. The prognostic value of E-cadherin in gastric cancer: a meta-analysis. Int. J. Cancer 132 (2013), 2589–2596.
175. Yanagisawa, M., Anastasiadis, P.Z., p120 catenin is essential for mesenchymal cadherin-mediated regulation of cell motility and invasiveness. J. Cell Biol. 174 (2006), 1087–1096.
176. Yang, S.Z., Kohno, N., Kondo, K., Yokoyama, A., Hamada, H., Hiwada, K., et al. Adriamycin activates E-cadherin- mediated cell–cell adhesion in human breast cancer cells. Int. J. Oncol. 15 (1999), 1109–1115.
177. Yang, Y.L., Chen, M.W., Xian, L., Prognostic and clinicopathological significance of downregulated E-cadherin expression in patients with non- small cell lung cancer (NSCLC): a meta-analysis. PLoS One, 9, 2014, e99763.
178. Yao, D., Peng, S., Dai, C., The role of hepatocyte nuclear factor 4alpha in metastatic tumor formation of hepatocellular carcinoma and its close relationship with the mesenchymal?epithelial transition markers. BMC Cancer, 13, 2013, 432.
179. Yates, C.C., Shepard, C.R., Stolz, D.B., Wells, A., Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br. J. Cancer 96 (2007), 1246–1252.
180. Yeh, Y.C., Wu, C.C., Wang, Y.K., Tang, M.J., DDR1 triggers epithelial cell differentiation by promoting cell adhesion through stabilization of E-cadherin. Mol. Biol. Cell 22 (2011), 940–953.
181. Yin, H., Kanasty, R.L., Eltoukhy, A.A., Vegas, A.J., Dorkin, J.R., Anderson, D.G., Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15 (2014), 541–555.
182. Younis, L.K., El Sakka, H., Haque, I., The prognostic value of E-cadherin expression in breast cancer. Int. J. Health Sci. 1 (2007), 43–51.
183. Yuecheng, Y., Hongmei, L., Xiaoyan, X., Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin. Exp. Metastasis 23 (2006), 65–74.
184. Zhang, J., Li, X., Huang, L., Non-viral nanocarriers for siRNA delivery in breast cancer. J. Control. Release 190 (2014), 440–450.
185. Zhang, Z., Yang, C., Gao, W., Chen, T., Qian, T., Hu, J., et al. FOXA2 attenuates the epithelial to mesenchymal transition by regulating the transcription of E-cadherin and ZEB2 in human breast cancer. Cancer Lett. 361 (2015), 240–250.
186. Zhao, C., Bu, X., Promoter methylation of tumorrelated genes in gastric carcinogenesis. Histol. Histopathol. 27 (2012), 1271–1282.
187. van Roy, F., Berx, G., The cell–cell adhesion molecule E-cadherin. Cell Mol. Life Sci. 65 (2008), 3756–3788.
188. van der Post, R.S., Vogelaar, I.P., Carneiro, F., Guilford, P., Huntsman, D., Hoogerbrugge, N., et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J. Med. Genet. 52 (2015), 361–374.